In the last trading session, the stock of Vaxart (VXRT) surged from $6.91 to $7.33, reaching the highest mark of $7.54 yesterday, on June 7. Can companies like VXRT succeed in creating a vaccine in late 2021, despite the fact, that corporations have already released COVID-19 vaccines?
Experts from Wall Street are betting that the company’s stock will have a growth of 94% in the coming years. Vaxart is creating oral recombinant vaccines in particular, rather than vaccinations that are provided by injection. Pills should be considerably easier to distribute and administer than injections, which might eliminate issues like aversion to injections and lack of vaccination availability. Moreover, the tests signaled, that Vaxart’s oral treatment might be effective against COVID-19 variants.
Thus, they have the opportunity internationally right away to get into these areas where there is still is not enough vaccine. Probably it is too early to get enthusiastic about Vaxart; however, it is undoubtedly a name to keep an eye on.